Many people think that participating in a research study means they will get better treatment for their illness. While this may be true, it’s important to remember that a research study is conducted for research purposes—it does not ensure better or safer treatment. Taking part in a study does not guarantee individual benefits to the participant in the form of newer or safer treatment. The contribution made participating in a research study is to science first and to the patient second.

DBSA, its advisors, and its consultants do not endorse or recommend the use of any specific treatment or medication. For advice about a specific treatment or medication, patients should consult their physicians and/or mental health professionals.

A comparison of mental health stigma across culturally similar countries

Have you experienced a mental health concern?

Western Sydney University is conducting research into stigma and mental health. We are looking at stigma in a number of countries and asking people who have had mental health concerns to use their personal experience to help us to understand mental health stigma better.

You are invited to participate in the study:

“A comparison of mental health stigma across culturally similar countries”

This research has been approved by the Human Research and Ethics Committee of Western Sydney University H13333 We will ask you to complete a survey which will take approximately 10 -15 minutes. Your responses to this survey are anonymous; no identifying information about you will be collected.

Dr.Lorraine Ivancic


Dr.Roy Laube

Begin Survey 

Deadline for Enrollment: September 13, 2019

Adolescent Schizophrenia Clinical Trial

Do you have a loved one between the ages of 13-17 who has been diagnosed with Schizophrenia or has symptoms of Schizophrenia? Are you interested in joining a clinical research study that may  increase our understanding of the disease?

This study is designed to evaluate the safety and efficacy of an investigational drug, called brexpiprazole, for adolescent patients diagnosed with Schizophrenia. The study will compare this medication with an active control (ABILIFY® (aripiprazole)) and placebo.

In order for your child to take part in the clinical research study, you will need to review the full checklist of criteria found on the eligibility page. Some of the basic criteria that must be met are:

  • Be 13-17 years old
  • Have a diagnosis or symptoms of schizophrenia that has been confirmed by their doctor
  • Do not have a diagnosis of autism, bipolar disorder, schizoaffective disorder, pervasive developmental disorder (PDD), OCD, or PTSD that has been the primary focus of treatment within 3 months of screening.
  • Do not have a history of seizures, epilepsy, stroke, or head trauma.

Other requirements will be reviewed in detail with you by the Study Center staff, if your child meets the requirements above and attends a screening visit.

Begin Screening

Deadline for Enrollment: February 2020

Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder (NERF) (Cincinnati, Ohio)

The purpose of this research study is to investigate brain changes in adolescents who are currently experiencing Attention Deficit Hyperactive Disorder (ADHD) symptoms and have a family history of bipolar disorder. Eligible participants will be randomized to mixed amphetamine salts or placebo for 12-week treatment. Study procedures will include MRI scans, blood draws and ECGs. All study procedures and medications will be provided at no cost to the participant. Participants may be compensated up to $280 for their participation.

Participants will be restricted from taking specific medications during the study, no other treatments will be restricted. Participants have a 50% chance of being randomized to the placebo group. This will last for the entirety of the study, up to 12 weeks, or until participant withdraws from the study.


Leah Fleischer

Deadline for Enrollment: 01/01/2020

Supporting your recovery during the COVID-19 crisis

COVID-19 Resources